Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment
- PMID: 20082998
- DOI: 10.1016/S1353-8020(09)70821-1
Emergencies in parkinsonism: akinetic crisis, life-threatening dyskinesias, and polyneuropathy during L-Dopa gel treatment
Abstract
This article reviews literature on three emergencies in Parkinson's disease (PD): Akinetic crisis, severe dyskinesias or life-threatening dyskinesias, and polyneuropathy during duodenal L-Dopa gel infusion treatment. Akinetic crisis is also known as Parkinsonian hyperpyrexia, Neuroleptic-like malignant syndrome, Acute akinesia, and Malignant syndrome in parkinsonism. It appears in 0.3% of PD patients/year, and is characterized in the most severe cases by total akinesia with dysphagia, hyperthermia, dysautonomia, increment of muscle enzymes and alterations of mental status, but it may also appear in less severe forms ("forme frusta"). At difference with the continuum of motor hypokinesias observed in PD it is characterized by transient (in cases with favorable outcome) unresponsiveness to rescue drugs. Life-supporting measures are mandatory in patients affected by this emergency. Severe dyskinesia, or life-threatening dyskinesia, is due to increased dopaminergic stimulation (either by the patient or by the prescriber): when it appears the level of dopaminomimetic stimulation should be reduced. Polyneuropathy during duodenal L-Dopa gel infusion is a recently described complication, attributed to the onset of Guillain-Barré syndromes. However, hemapheresis was not effective in some reported cases, and recent evidence suggests that Vitamin B12 deficiency or direct high-dose chronic L-Dopa toxicity might play a role in its origin.
Similar articles
-
[Development of dyskinesias induced by treatment for Parkinson's disease: potential role of first exposure to L-DOPA (or phenomenon of priming)].Rev Neurol (Paris). 2000 Mar;156(3):224-35. Rev Neurol (Paris). 2000. PMID: 10740093 Review. French.
-
[Social and economic cost of L-Dopa-induced dyskinesias in patients with Parkinson's disease].Rev Neurol (Paris). 2001 May;157(5):507-14. Rev Neurol (Paris). 2001. PMID: 11438770 French.
-
Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.Parkinsonism Relat Disord. 2009 Jul;15(6):445-52. doi: 10.1016/j.parkreldis.2008.11.001. Epub 2009 Feb 3. Parkinsonism Relat Disord. 2009. PMID: 19196540
-
Treatment of Parkinson's disease: levodopa as the first choice.J Neurol. 2002 Sep;249 Suppl 2:II19-24. doi: 10.1007/s00415-002-1204-4. J Neurol. 2002. PMID: 12375059 Review.
-
[Current preclinical findings on substances against Parkinson's disease].Nervenarzt. 2003 Mar;74 Suppl 1:S2-6. doi: 10.1007/s00115-003-1481-x. Nervenarzt. 2003. PMID: 12624677 German.
Cited by
-
Critical Illness Neuromyopathy Complicating Akinetic Crisis in Parkinsonism: Report of 3 Cases.Medicine (Baltimore). 2015 Jul;94(28):e1118. doi: 10.1097/MD.0000000000001118. Medicine (Baltimore). 2015. PMID: 26181547 Free PMC article.
-
Elevation of total homocysteine levels in patients with Parkinson's disease treated with duodenal levodopa/carbidopa gel.J Neural Transm (Vienna). 2011 Sep;118(9):1329-33. doi: 10.1007/s00702-011-0614-9. Epub 2011 Feb 27. J Neural Transm (Vienna). 2011. PMID: 21359971 Clinical Trial.
-
Covid-19 and Parkinson's disease: Acute clinical implications, long-COVID and post-COVID-19 parkinsonism.Int Rev Neurobiol. 2022;165:63-89. doi: 10.1016/bs.irn.2022.04.004. Epub 2022 Aug 8. Int Rev Neurobiol. 2022. PMID: 36208907 Free PMC article.
-
Emergencies and critical issues in Parkinson's disease.Pract Neurol. 2020 Feb;20(1):15-25. doi: 10.1136/practneurol-2018-002075. Epub 2019 Aug 19. Pract Neurol. 2020. PMID: 31427383 Free PMC article. Review.
-
Clinical features, pathophysiology, and treatment of levodopa-induced dyskinesias in Parkinson's disease.Parkinsons Dis. 2012;2012:943159. doi: 10.1155/2012/943159. Epub 2012 Oct 17. Parkinsons Dis. 2012. PMID: 23125942 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources